OXURION (EBR:OXUR) | WebDisclosure

Basculer en Français

10093	Companies
206623	Keywords
136808	Articles
109530	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 08/04/2025 at 18:00, 7 months 21 days ago

Oxurion kondigt aan dat het een verbeterd indicatief financieringsaanbod van EUR 30 miljoen heeft gekregen om de diversificatie van een deel van zijn kasmiddelen naar digitale activa te starten
Oxurion NV ontvangt een verbeterd financieringsaanbod van €30 miljoen van Atlas Special Opportunities voor investering in digitale activa. Financiering in tien schijven via converteerbare obligaties om kasmiddelen te diversifiëren

Atlas Special Opportunities Oxurion NV Converteerbare Obligaties Financieringsaanbod Digitale Activa
PRESS RELEASE

published on 08/04/2025 at 18:00, 7 months 21 days ago

Oxurion announces it obtained an improved indicative EUR 30 million financing offer to initiate its plan to diversify by allocating part of its treasury into digital assets
Oxurion NV receives €30 million financing offer from Atlas Special Opportunities for investment in digital assets. Company remains confident in closing the transaction by August 2025

Investment Digital Assets Oxurion NV Financing Offer August 2025
BRIEF

published on 08/04/2025 at 08:35, 7 months 22 days ago

Oxurion conclut l'acquisition de 72% d'Axiodis CRO

Acquisition Croissance Externe Données Cliniques Oxurion Axiodis CRO
BRIEF

published on 08/04/2025 at 08:35, 7 months 22 days ago

Oxurion completes acquisition of 72% of Axiodis CRO

Acquisition External Growth Clinical Data Oxurion Axiodis CRO
PRESS RELEASE

published on 08/04/2025 at 08:30, 7 months 22 days ago

Oxurion finalise l'acquisition d'Axiodis CRO et accélère la structuration de son pôle européen dédié à la donnée clinique
Oxurion finalise l'acquisition de 72?% du capital d'Axiodis CRO, marquant la première étape vers un pôle intégré de donnée clinique en France et en Europe

Acquisition Stratégie De Croissance Biopharmaceutique Donnée Clinique Oxurion
PRESS RELEASE

published on 08/04/2025 at 08:30, 7 months 22 days ago

Oxurion completes the acquisition of Axiodis CRO and accelerates the structuring of its European clinical data platform
Oxurion completes the acquisition of 72% stake in Axiodis CRO, paving the way for an integrated platform focused on clinical data. Intensifies discussions with strategic targets in France and Europe

Acquisition Europe Intégration Clinical Data Oxurion
PRESS RELEASE

published on 08/04/2025 at 08:30, 7 months 22 days ago

Oxurion rondt overname van Axiodis CRO af en versnelt uitbouw van haar Europese platform voor klinische data
Oxurion schliesst erfolgreich die Übernahme von 72% des Aktienkapitals von Axiodis CRO ab und beschleunigt die Gespräche mit strategischen Partnern zur Schaffung eines integrierten Plattforms für klinische Daten

Übernahme Partnerschaften Oxurion Axiodis CRO Klinische Daten
BRIEF

published on 07/30/2025 at 18:05, 7 months 26 days ago

Oxurion Réceptionne une Notification de Transparence Modifiée

Actions Transparence Atlas Special Opportunities Oxurion Bio-pharmaceutique
BRIEF

published on 07/30/2025 at 18:05, 7 months 26 days ago

Oxurion Receives a Modified Transparency Notification

Actions Transparency Biopharmaceutical Atlas Special Opportunities Oxurion
PRESS RELEASE

published on 07/30/2025 at 18:00, 7 months 26 days ago

Oxurion ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities II LLC
Oxurion NV receives transparency notification from Atlas Special Opportunities II LLC regarding shareholding threshold

Transparency Notification Shareholding Belgium Oxurion NV Atlas Special Opportunities II LLC

Accesswire

Published on 03/26/2026 at 08:05, 1 hour 32 minutes ago

Vanta Announces U.S. Ticker Symbol Change to VNTXF
Published on 03/26/2026 at 04:55, 4 hours 42 minutes ago

Vanta Announces Capital Markets Initiatives to Strengthen Financial Position and Support Growth Initiatives
Published on 03/26/2026 at 00:40, 8 hours 57 minutes ago

Challenger RC Resource Upgrade Drilling Complete
Published on 03/26/2026 at 00:30, 9 hours 7 minutes ago

Nano One Highlights Recent Objectives & Reports Fourth Quarter 2025 Results
Published on 03/25/2026 at 19:15, 14 hours 22 minutes ago

Gemina Laboratories Ltd. Announces Delisting from the CSE

View all ACCESSWIRE

EQS Group

Published on 03/26/2026 at 09:20, 17 minutes ago

yoummday Wins a Texas Instruments 2025 Supplier Excellence Award
Published on 03/26/2026 at 09:10, 27 minutes ago

Uppsala first in the world with IQ tourism
Published on 03/26/2026 at 09:05, 32 minutes ago

Rockwell Automation Showcases Autonomous Industrial Operations at Hannover Messe 2026
Published on 03/26/2026 at 09:00, 36 minutes ago

Original-Research: ZEAL Network SE (von NuWays AG): BUY
Published on 03/26/2026 at 09:00, 36 minutes ago

Original-Research: INDUS Holding AG (von NuWays AG): BUY

Les Echos

Published on 03/26/2026 at 08:57, 40 minutes ago

Communiqué Edenred
Published on 03/26/2026 at 08:57, 40 minutes ago

Edenred statement
Published on 03/26/2026 at 07:30, 2 hours 7 minutes ago

BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/26/2026 at 07:30, 2 hours 7 minutes ago

BIOPHYTIS ET LYNXKITE INVITÉS À LA CONFÉRENCE NVIDIA : L’IA AU SERVICE DE LA LONGÉVITÉ
Published on 03/25/2026 at 18:53, 14 hours 43 minutes ago

CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026

View all LES ECHOS COMFI WIRE